Search Patents
  • CATALYTIC CANNABIGEROL PROCESSES AND PRECURSORS
    Publication number: 20230105720
    Abstract: The present disclosure relates to cannabigerol sulfonate esters and processes for their use to prepare cannabigerol (CBG) and related compounds, including cannabigerobutol (CBGB), cannabigerovarin (CBGV), and cannabigerophorbol (CBGP). In a preferred embodiment, the cannabigerol sulfonate ester is (E)-4-(3, 7-5 dimethylocta-2,6-dienyl)-3,5-bis(trimethylsilyloxy)phenylromethanesulfonate. In a preferred process, the trifluoromethansulfonate leaving group is replaced by an alkyl group. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabigerol and related compounds from the cannabigerol sulfonate esters.
    Type: Application
    Filed: March 29, 2021
    Publication date: April 6, 2023
    Applicant: KARE CHEMICAL TECHNOLOGIES INC.
    Inventors: Kamaluddin ABDUR-RASHID, Wenli JIA, Kareem ABDUR-RASHID
  • CANNABIGEROL AND PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL FOR USE IN THE TREATMENT OF INSOMNIA
    Publication number: 20220168235
    Abstract: The present invention relates to cannabigerol (CBG), a cannabinoid, for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity, preferably wherein the ratio of CBG:CBND by weight is between 10:1 and 1:10.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 2, 2022
    Inventor: Ronald Johannes GLAS
  • METHOD FOR SIMULTANEOUSLY SEPARATING CANNABIDIVARIN AND CANNABIGEROL
    Publication number: 20220315512
    Abstract: The present invention relates to a method for simultaneously separating cannabidivarin and cannabigerol, comprising: sufficiently oscillating a solvent system, allowing the solvent system to stand, and separately collecting an upper phase and a lower phase; dissolving a commercially available industrial hemp full-spectrum refined oil into the upper phase, performing separation using high-speed countercurrent chromatography with the upper phase as a stationary phase and the lower phase as a mobile phase to obtain a mixture of cannabidivarin and the mobile phase and a mixture of cannabigerol and the mobile phase, respectively, and removing the mobile phase to obtain cannabidivarin and cannabigerol. The present invention uses high-speed countercurrent chromatography to simultaneously separate and purify to obtain cannabidivarin (CBDV) with the purity of greater than 98% and cannabigerol (CBG) with the purity of greater than 97% from the industrial hemp full-spectrum refined oil for the first time.
    Type: Application
    Filed: September 8, 2020
    Publication date: October 6, 2022
    Applicant: Shanghai Tauto Biotech Co., Ltd.
    Inventors: Li DENG, Qi YU
  • SYNTHESIS AND PURIFICATION OF CANNABIGEROL AND ITS APPLICATION
    Publication number: 20220296482
    Abstract: The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 22, 2022
    Inventors: Stefan BRAND, Matthias WINKLER, Marcus Rudolf GÖTZ
  • CRYSTALLINE CANNABIGEROL
    Publication number: 20220242810
    Abstract: The application relates to crystalline cannabigerol comprising at least one X-ray powder diffraction peak selected from the group consisting of 4.73°, 9.52°, 14.30°, and 23.93° 2?(each ±0.20° 2?), to methods of making the crystalline cannabigerol and its medical uses.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 4, 2022
    Inventors: Wen-Chun Zhang, Phillip Wilkerson, Gnel Mkrtchyan
  • PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL
    Publication number: 20080031977
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: June 8, 2007
    Publication date: February 7, 2008
    Applicant: GW Pharma Limited
    Inventors: Richard Musty, Richard Deyo
  • PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL
    Publication number: 20140039043
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: February 6, 2014
    Applicant: GW Pharma Limited
    Inventor: GW Pharma Limited
  • Pharmaceutical compositions comprising cannabigerol
    Patent number: 8481085
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 9, 2013
    Assignee: GW Pharma Limited
    Inventors: Richard Musty, Richard Deyo
  • Synthesis of Cannabigerol
    Publication number: 20210276936
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 9, 2021
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • SYNTHESIS OF CANNABIGEROL
    Publication number: 20200115306
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • Synthesis of cannabigerol
    Patent number: 11040932
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 22, 2021
    Assignee: Treehouse Biotech, Inc.
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • Cannabis Plants with a Cannabinoid Profile Enriched for Delta-9-Tetrahydrocannabinol and Cannabigerol
    Publication number: 20210400895
    Abstract: The present disclosure relates to new Cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., ?-9-tetrahydrocannabinol (THC) and ?-9-tetrahydrocannabinolic acid (THCA)) and total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)).
    Type: Application
    Filed: November 8, 2019
    Publication date: December 30, 2021
    Inventors: Aaron Christopher Elkins, Simone Jane Rochfort, Noel Cogan, German Carlos Spangenberg
  • Cannabis Plants with a Cannabinoid Profile Enriched for Delta-9-Tetrahydrocannabinol, Cannabigerol and Tetrahydrocannabivarin
    Publication number: 20220000056
    Abstract: The present disclosure relates generally to new cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., ?-9-tetrahydrocannabinol (THC) and ?-9-tetrahydrocannabinolic acid (THCA), total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)), and total THCV (i.e., tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA)).
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Inventors: Aaron Christopher Elkins, Simone Jane Rochfort, Noel Cogan, German Carlos Spangenberg
  • Cannabigerol (CBG) products and methods of use
    Patent number: 11890311
    Abstract: A cannabinoid composition, comprising a full spectrum extract of a plant of genus cannabis comprising at least 5% by weight cannabigerol, comprising cannabis terpenes and cannabis flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, sublingual, inhaled, vaporized, or smoked administration. The formulation may include absorption or pharmacological enhancers e.g., curcumin, resveratrol, quercitin, piperine and/or N-alkylamides. The composition has anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to SARS-Cov2 infection.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: February 6, 2024
    Assignee: Bazelet Health Systems, Inc.
    Inventors: Michael Elzufon, Howard Hoffberg
  • COSMETIC AND TOPICAL COMPOSITIONS COMPRISING CANNABIGEROL
    Publication number: 20200188325
    Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 18, 2020
    Inventors: Lekhram Changoer, George Anastassov
  • COSMETIC AND TOPICAL COMPOSITIONS COMPRISING CANNABIGEROL
    Publication number: 20160235661
    Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • THERAPEUTIC USES OF CANNABIGEROL
    Publication number: 20100292345
    Abstract: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 18, 2010
    Applicant: GW PHARMA LIMITED
    Inventor: Roger Pertwee
  • Cannabigerol derivatives
    Patent number: 9802880
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: October 31, 2017
    Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
  • Methods of synthesizing cannabigerol, cannabigerolic acid, and analogs thereof
    Patent number: 11795128
    Abstract: Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: October 24, 2023
    Inventors: Daniel Brumar, Mahmood Azizpour Fard, Ben Geiling, Mohammadmehdi Haghdoost Manjili
  • NOVEL CANNABIGEROL DERIVATIVES
    Publication number: 20170247308
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Application
    Filed: February 12, 2015
    Publication date: August 31, 2017
    Applicant: VIVACELL BIOTECHNOLOGY ESPAÑA S.L.
    Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
Narrow Results

Filter by US Classification